Skip to main content
Hepion Pharmaceuticals’ CEO Robert Foster discusses CRV431’s potential in NASH [BioTuesdays]
https://www.biotuesdays.com/features/2019/7/30/hepion-pharmaceuticals-ceo-robert-foster-discusses-crv431s-potential-in-nash
Robert Foster swinging for the fence again with Hepion Pharma [BioTuesdays]
http://www.biotuesdays.com/features/2018/11/7/robert-foster-swinging-for-the-fence-again-with-contravir-pharma
TXL for hepatitis B safe, effective in phase 2a study [via Healio]
http://www.healio.com/hepatology/viral-hepatitis/news/online/%7B16ae8488-4b93-459f-94b1-197f2dd77d75%7D/txl-for-hepatitis-b-safe-effective-in-phase-2a-study
An Update on Hepatitis B Therapies [Drug Discovery World]
http://www.ddw-online.com/fall-2016/p315872-an-update-on-hepatitis-b-therapies.html
Dr. Robert Foster, Chief Scientific Officer of Hepion, invited to join the Faculty of Pharmacy & Pharmaceutical Sciences at the University of Alberta as an Honorary Professor
https://hepionpharma.com/wp-content/uploads/2016/07/RTF-Professorship.pdf
The Rise of the CFO Strategist: Balancing Numbers and Know-how [Via PharmaExec]
http://www.pharmexec.com/rise-cfo-strategist-balancing-numbers-and-know-how
Hepion Hopes To Establish Backbone For Hepatitis B Combo Therapy [via Scrip]
https://scrip.pharmamedtechbi.com/SC096933/Hepion-Hopes-To-Establish-Backbone-For-Hepatitis-B-Combo-Therapy
Should Gilead Sciences Feel Threatened By Hepion’s Hepatitis B Drug? [via Bidness Etc]
http://www.bidnessetc.com/66362-gilead-sciences-feel-threatened-contravirs-hepatitis-b-drug/
Hepatitis Quest Moves From C to B Under Ex-Gilead Leaders [via Bloomberg Business]
http://www.bloomberg.com/news/articles/2015-02-04/hepatitis-quest-moves-from-c-to-b-under-former-gilead-executives
